Drug intelligence / Profile preview

KAN-ONCO-05

Development stage: Preclinical
Lead developer: Kantify
Modality: Small Molecules

Overview

KAN-ONCO-05 is a small molecule kinase inhibitor currently in preclinical development for the treatment of various cancers (Pan Cancer). Discovered using Kantify's proprietary Sapian™ AI platform, the drug is being developed in collaboration with the Institut Necker (INSERM). The program aims to leverage AI-driven drug discovery to identify and optimize potent inhibitors against specific kinase targets involved in oncogenic signaling pathways. As of early 2024, the candidate is undergoing in/ex vivo validation.

Beyond the preview

Go deeper on KAN-ONCO-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAN-ONCO-05.